Eli Lilly to unveil major breast cancer data at SABCS 2025
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Consolidated revenue from operations stood at Rs. 111.05 crore
Total income for the period stood at Rs. 7101.28 crore
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Subscribe To Our Newsletter & Stay Updated